



RESOLUTION EXCLUSION OF THE TENDER UNDER PROCEDURE NUM. 2025-031 RELATING TO THE SERVICE OF DNA AND RNA SEQUENCING AND SPECIALIZED BIOINFORMATIC ANALYSIS FROM TUMOR SAMPLES AND WHOLE BLOOD IN THE FUNDACIÓ HOSPITAL UNIVERSITARI VALL HEBRON - INSTITUT DE RECERCA (VHIR).

Proyecto "PI23/01045", financiado por el Instituto de Salud Carlos III (ISCIII) y cofinanciado por la Unión Europea.



2025-031 DNA AND RNA SEQUENCING (PI23/01045)

BACKGROUND

- I.- Ms. Montserrat Gimenez Prous, in her capacity as Manager of the Vall Hebron University Hospital Foundation Research Institute (VHIR), and as the contracting body of the aforementioned entity, called for an open procedure relating to of service of Next generation sequencing service and data analysis and report including DNA and RNA sequencing from human tumour samples, paired with sequencing of peripheral blood samples as a control sample by the Project PI23/01045 titled "Plataforma integrativa multiómica para la identificación de biomarcadores predictivos de respuesta a quimioterapia e inmunoterapia en cáncer de mama triple negativo temprano (PORTRAIT-TNBC)" of the Fundació Hospital Universitari Vall Hebron-Institut de Recerca (VHIR), funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, by means of announcements to the VHIR Contracting Party Profile and to the Public Contracting Platform of the Generalitat de Catalunya on 16th July of 2025.
- **II.-** On 11th August of 2025, the Contracting Committee was constituted and proceeded to the examination and qualification of the administrative documentation of the bidding companies.
- **III.-** On 18th of August of 2025, the Contracting Committee was constituted to the opening of the envelope containing the documentation related to the award criteria evaluated by means of a value judgment.
- **IV.-** Prior to the Opening of Envelope No. 3, the bidders have been notified through the entity's Contractor Profile, the result of envelopes No. 2, which contain the award criteria to be weighted by a value judgment, the result of which, and according to the technical evaluation report dated on 29th of August of 2025, as follows:

In accordance with Clause 12 of the Document of Technical Specifications, on 26th August of 2025, a question was sent to bidder company **Sequentia Biotech SL**, requesting it to clarify whether the service related to the sequencing of tumor genomic DNA and normal blood DNA (reference DNA), and the RNA sequencing from the same piece of tumoral tissue will be carried out by the subcontracted company.





After the reply to the clarification within the deadline by the bidder Sequentia Biotech SL, the company replied that the service related to the sequencing of tumor genomic DNA and normal blood DNA (reference DNA), and the RNA sequencing from the same piece of tumoral tissue will be carried out by the subcontracted company.

In accordance with the provisions of Clause 22 of the Document of Technical Specifications:

1. The successful tenderer may only subcontract the partial performance of the contract, which does not constitute the main object of the service tendered for.

Consequently, it was proposed that company Sequentia Biotech SL be excluded for non-compliance of the Clause 22 of the Document of Technical Specifications.

V.- On 3rd of September of 2025, the Contracting Committee proposed to exclude the bidding company **SEQUENTIA BIOTECH SL** from this open tendering procedure for noncompliance of the Clause 22 of the Document of Technical Specifications.

For the foregoing reasons


AGREES,

FIRST.- EXCLUDE the company SEQUENTIA BIOTECH SL of the present tender process relating to the service of Next generation sequencing service and data analysis and report including DNA and RNA sequencing from human tumour samples, paired with sequencing of peripheral blood samples as a control sample by the Project PI23/01045 titled "Plataforma integrativa multiómica para la identificación de biomarcadores predictivos de respuesta a quimioterapia e inmunoterapia en cáncer de mama triple negativo temprano (PORTRAIT-TNBC)" of the Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR), funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, for non-compliance of the Clause 22 of the Document of Technical Specifications.

SECOND.- TO NOTIFY the exclusion of the company from the tender procedure in question, to the company **SEQUENTIA BIOTECH SL**.

THIRD.- TO PUBLISH this agreement in the profile of the contracting party on the website of the Vall Hebron University Hospital Foundation - Research Institute (VHIR) www.vhir.org, as well as in the profile of the contracting party, which appears on the Public Contracting Platform of the Generalitat de Catalunya http://contractaciopublica.gencat.cat.

Against this resolution, the interested parties may lodge a special appeal in matters of contracting before the contracting body or the Catalan Public Sector Contracts Court, within 15 working days from the day following the day after its notification is sent, in accordance with article 44 of Law 9/2017, of 8 November on Public Sector Contracts.







Alternatively, they may lodge a contentious-administrative appeal before the Contentious-Administrative Chamber of the High Court of Justice of Catalonia, within two months of the day following notification, in accordance with the provisions of article 46.1 of Law 29/1998, of 13 July, regulating contentious-administrative jurisdiction.

Barcelona, at the date of digital signature

CONTRACTING ORGANISM
Mrs. Montserrat Gimenez Prous
Manager
Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR)